2:06 PM
 | 
Jan 03, 2018
 |  BC Extra  |  Company News

Sangamo, Pfizer partner for ALS therapy

Sangamo Therapeutics Inc. (NASDAQ:SGMO) and Pfizer Inc. (NYSE:PFE) partnered to develop a therapy using Sangamo's zinc finger protein transcription factor (ZFP-TF) gene regulation technology to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of chromosome 9 open reading frame 72 (C9orf72).

Sangamo will...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >